<\/p>\n
Lipaglyn<\/strong> je zna\u010dka saroglitazar<\/strong> (4 mg), a dual PPAR-α\/γ agonist<\/strong> developed in India (approved 2013). It is unique: predominantly a PPAR-α agonist (like fibrates) with partial PPAR-γ agonism (like pioglitazone). Used for diabetic dyslipidaemia<\/strong> (elevated triglycerides with type 2 diabetes) and non-alcoholic fatty liver disease (NAFLD\/NASH)<\/strong> — approved in India for both indications. Lowers triglycerides by 40–50%, raises HDL, reduces HbA1c by ~0.5 points, and improves liver fat and enzymes. One tablet (4 mg) once daily before food. Does not cause hypoglycaemia. Generally well-tolerated — mild GI upset, rare weight gain. Not a substitute for statins<\/strong> in primary lipid lowering. Avoid in severe hepatic impairment, pregnancy, and known hypersensitivity.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Lipaglyn is an oral dual PPAR-α\/γ agonist<\/strong> obsahuj\u00edc\u00ed saroglitazar<\/strong> (4 mg), developed by Zydus Cadila (India) and approved in India in 2013. Available in packs of 30, 60, 90 or 180 tablets. It is prescribed for:<\/p>\n Saroglitazar is unique because it is the first dual PPAR-α\/γ agonist to reach market. Previous attempts (muraglitazar, tesaglitazar) were abandoned due to safety concerns; saroglitazar’s balanced profile (mostly α, partial γ) appears to avoid them.<\/p>\n Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that control gene expression in lipid and glucose metabolism. Saroglitazar activates two of them:<\/p>\n The net effect is improvement in both<\/em> the lipid profile and glycaemic control of diabetic dyslipidaemia in a single tablet. Importantly, because PPAR-γ activation is only partial, the weight gain and fluid-retention seen with pioglitazone are much less common.<\/p>\n Standardn\u00ed d\u00e1vka:<\/strong> one 4 mg tablet once daily, approximately one hour before food (in the morning).<\/p>\n Saroglitazar is generally well-tolerated.<\/p>\n \u010cast\u00e9:<\/strong><\/p>\n M\u00e9n\u011b \u010dast\u00e9:<\/strong><\/p>\n No clear signal of heart failure or bladder cancer (unlike pioglitazone). No outcome-trial CV data yet, but the limited trials to date are reassuring.<\/p>\n Store Lipaglyn below 30°C in a dry place, in the original blister. Keep out of reach of children.<\/p>\n Both are PPAR agonists, but with different selectivity. Pioglitazone is primarily PPAR-γ (strong insulin-sensitiser, weight gain, fluid retention). Saroglitazar is primarily PPAR-α with partial<\/em> PPAR-γ (strong triglyceride-lowering, modest insulin-sensitising, far less weight gain and oedema). For a patient with diabetic dyslipidaemia, saroglitazar has the stronger lipid effect; for pure insulin resistance with normal lipids, pioglitazone is still more commonly used.<\/p>\n No — saroglitazar and statins target different lipid abnormalities. Statins lower LDL-cholesterol (the main atherogenic lipid); saroglitazar lowers triglycerides and raises HDL. In diabetic patients with mixed dyslipidaemia, the two are typically used together.<\/p>\n Yes — saroglitazar has approved indications for NAFLD\/NASH in India based on Indian trial data showing reductions in ALT, liver fat on MRI-PDFF, and improvement in fibrosis markers. It is one of the few oral treatments with regulatory approval for NASH anywhere.<\/p>\n Not on its own — saroglitazar does not stimulate insulin release. Hypoglycaemia only becomes a concern in combination with a sulfonylurea, meglitinide, or insulin.<\/p>\n Saroglitazar is approved primarily in India, with some approvals in Mexico and a few other countries. It is not yet approved in the US, EU, UK, or Australia — those agencies have not completed review. Clinically, the drug has been used in over 2 million patient-years in India with a good safety record.<\/p>\n You can order Lipaglyn (4 mg) from MedsBase in packs of 30, 60, 90 or 180 tablets. We ship worldwide, with discreet packaging and genuine WHO-GMP certified manufacturer stock.<\/p>\n <\/p>\n Dal\u0161\u00ed produkty v Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n \u2705 Manages lipid levels Lipaglyn contains Saroglitazar.<\/p>","protected":false},"featured_media":59204,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3230,3231],"product_tag":[4645,4646],"class_list":{"0":"post-59203","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-diabetes","9":"product_cat-diabetes-medication","10":"product_tag-lipaglyn","11":"product_tag-saroglitazar","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/59203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=59203"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/59204"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=59203"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=59203"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=59203"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=59203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
What Is Lipaglyn?<\/h2>\n
\n
How Does Lipaglyn Work?<\/h2>\n
\n
D\u00e1vkov\u00e1n\u00ed a pod\u00e1n\u00ed<\/h2>\n
\n
Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n
\n
\n
Interakce s l\u00e9\u010divy<\/h2>\n
\n
Who Should Not Take Lipaglyn?<\/h2>\n
\n
Skladov\u00e1n\u00ed<\/h2>\n
\u010casto kladen\u00e9 dotazy<\/h2>\n
How does saroglitazar differ from pioglitazone?<\/h3>\n
Can Lipaglyn replace my statin?<\/h3>\n
Does Lipaglyn help fatty liver or NASH?<\/h3>\n
Does Lipaglyn cause hypoglycaemia?<\/h3>\n
Is Lipaglyn approved outside India?<\/h3>\n
Where can I buy Lipaglyn online?<\/h3>\n
Related Diabetes and Lipid Medications<\/h2>\n
\n
Souvisej\u00edc\u00ed alternativy<\/h3>\n
\n
\n\u2705 Controls blood sugar
\n\u2705 Reduces cardiovascular risk
\n\u2705 Zlep\u0161uje citlivost na inzul\u00edn
\n\u2705 Enhances metabolic health<\/p>\n